Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials

Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumhäkel, Magnus, Böhm, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141911/
https://www.ncbi.nlm.nih.gov/pubmed/21796253
http://dx.doi.org/10.2147/VHRM.S17168
_version_ 1782208773658509312
author Baumhäkel, Magnus
Böhm, Michael
author_facet Baumhäkel, Magnus
Böhm, Michael
author_sort Baumhäkel, Magnus
collection PubMed
description Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.
format Online
Article
Text
id pubmed-3141911
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31419112011-07-27 Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials Baumhäkel, Magnus Böhm, Michael Vasc Health Risk Manag Review Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk. Dove Medical Press 2011 2011-06-23 /pmc/articles/PMC3141911/ /pubmed/21796253 http://dx.doi.org/10.2147/VHRM.S17168 Text en © 2011 Baumhäkel and Böhm, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Baumhäkel, Magnus
Böhm, Michael
Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title_full Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title_fullStr Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title_full_unstemmed Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title_short Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
title_sort cardiovascular outcomes with angiotensin ii receptor blockers: clinical implications of recent trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141911/
https://www.ncbi.nlm.nih.gov/pubmed/21796253
http://dx.doi.org/10.2147/VHRM.S17168
work_keys_str_mv AT baumhakelmagnus cardiovascularoutcomeswithangiotensiniireceptorblockersclinicalimplicationsofrecenttrials
AT bohmmichael cardiovascularoutcomeswithangiotensiniireceptorblockersclinicalimplicationsofrecenttrials

Ejemplares similares